Related Experiment Videos

Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke

Ken Johkura1, Tamaki N Yoshida, Yosuke Kudo

  • 1Department of Neurology and Stroke Center, Hiratsuka Kyosai Hospital, Hiratsuka, Japan. johkura-k@kr.hiratsuka.kanagawa.jp

Clinical Neurology and Neurosurgery
|February 17, 2012
PubMed

Insights

Cilostazol significantly improved chronic dizziness after ischemic stroke compared to aspirin. It also enhanced brain blood flow and cerebral function, aiding balance adaptation.

Area of Science:

  • Neurology
  • Vascular Neurology
  • Neurorehabilitation

Background:

  • Chronic dizziness is a common sequela following ischemic stroke.
  • Current treatments for post-stroke dizziness lack definitive efficacy.

Purpose of the Study:

  • To compare the efficacy of cilostazol versus aspirin in treating chronic dizziness post-ischemic stroke.
  • To evaluate the impact of these treatments on neurophysiological and hemodynamic markers.

Main Methods:

  • A prospective, randomized, open-label trial involving 106 patients with recent supratentorial ischemic stroke and persistent dizziness.
  • Patients received either cilostazol (200mg/day) or aspirin (100mg/day) for six months.
  • Outcomes included dizziness improvement, vestibulo-ocular reflex (VOR) fixation suppression, regional cerebral blood flow (CBF), and depression scores.

Main Results:

  • Cilostazol demonstrated significantly greater improvement in dizziness compared to aspirin (P<0.0001).
  • The cilostazol group showed improvements in VOR fixation suppression and increased supratentorial CBF.
  • No significant difference in depression scores was observed between the groups.

Conclusions:

  • Cilostazol is effective in treating chronic dizziness after ischemic stroke.
  • Cilostazol enhances supratentorial cerebral blood flow and improves cerebral function related to balance.
  • Cilostazol offers a potential therapeutic option for managing post-stroke dizziness.
Abstract

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...